Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Dr. Upadhyay brings over 25 years of global leadership experience across life sciences, regulated manufacturing, diagnostics, and research-led environments
Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
The company reported free cash flow of Rs. 2,590 Mn for FY26
The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
Subscribe To Our Newsletter & Stay Updated
